POS0781 EFFICACY AND SAFETY OF ORAL DEUCRAVACITINIB IN PATIENTS WITH CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS: RESULTS FROM PAISLEY CLE, A GLOBAL, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIALJ.F. Merola, V.P. Werth, Jürgen J. Wenzel et al.|Annals of the Rheumatic Diseases|2025Cited by 5
AB0982 DOMAINS FOR INCLUSION IN A NOVEL TREATMENT RESPONSE MEASURE FOR SYSTEMIC LUPUS ERYTHEMATOSUS (TRM-SLE): RESULTS OF A MODIFIED DELPHI STUDYKim A. Connelly, Maria Dall’Era, R. Koelmeyer et al.|Annals of the Rheumatic Diseases|2024Cited by 0